{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:34Z","timestamp":1793643334986,"version":"4.5.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40259-019-00398-7","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:02:26Z","timestamp":1575849746000},"page":"171-181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera\u00ae) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)"],"prefix":"10.1007","volume":"34","author":[{"given":"Jeff P.","family":"Sharman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahira","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Alcasid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Ann","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Aurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"398_CR1","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Silver Spring: US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2015. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf. Accessed 9 Jan 2019."},{"key":"398_CR2","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf. Accessed 9 Jan 2019."},{"issue":"5","key":"398_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/ph7050530","volume":"7","author":"WH Baer II","year":"2014","unstructured":"Baer WH II, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014;7(5):530\u201344.","journal-title":"Pharmaceuticals (Basel)."},{"key":"398_CR4","unstructured":"IMS. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. 2016. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/03\/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf. Accessed 9 Jan 2019."},{"key":"398_CR5","unstructured":"Hoffmann-La Roche Ltd. MabThera (rituximab) summary of product characteristics. London. 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000165\/WC500025821.pdf. Accessed 9 Jan 2019."},{"key":"398_CR6","unstructured":"Genentech Inc. Rituxan\u00ae (rituximab) prescribing information. South San Francisco: Genentech Inc; 2013. http:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf. Accessed 9 Jan 2019."},{"key":"398_CR7","unstructured":"European Medicines Agency. European public assessment reports (EPAR) for human medicines: biosimilars. London: European Medicines Agency; 2018. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars. Accessed 17 May 2018."},{"key":"398_CR8","unstructured":"US Food and Drug Administration. FDA approves Truxima as biosimilar to Rituxan for non-Hodgkin\u2019s lymphoma. Silver Spring: US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2018. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm627035.htm. Accessed 9 Jan 2019."},{"key":"398_CR9","unstructured":"Pfizer Inc. Ruxience prescribing information. Pfizer Inc. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761103s000lbl.pdf Accessed 30 July 2019."},{"issue":"7","key":"398_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1177\/0192623313520351","volume":"42","author":"AM Ryan","year":"2014","unstructured":"Ryan AM, Sokolowski SA, Ng CK, Shirai N, Collinge M, Shen AC, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera\u00ae). Toxicol Pathol. 2014;42(7):1069\u201381.","journal-title":"Toxicol Pathol"},{"issue":"1","key":"398_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bcp.12916","volume":"82","author":"S Cohen","year":"2016","unstructured":"Cohen S, Emery P, Greenwald M, Yin D, Becker JC, Melia LA, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol. 2016;82(1):129\u201338.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"398_CR12","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/acr.23586","volume":"70","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Burgos-Vargas R, Emery P, Jin B, Cronenberger C, V\u00e1zquez-Abad MD. Extension study of PF-05280586, a potential rituximab biosimilar, versus rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018;70(11):1598\u2013606.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"398_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424\u201335.","journal-title":"Lancet Oncol."},{"key":"398_CR14","doi-asserted-by":"crossref","unstructured":"Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood. 2011;118(21):LBA-6.","DOI":"10.1182\/blood.V118.21.LBA-6.LBA-6"},{"key":"398_CR15","doi-asserted-by":"crossref","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Ha\u00efoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15(3):1110\u20137.","DOI":"10.1200\/JCO.1997.15.3.1110"},{"issue":"27","key":"398_CR16","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u201362.","journal-title":"J Clin Oncol"},{"issue":"5","key":"398_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"4","key":"398_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","volume":"47","author":"HA Sampson","year":"2006","unstructured":"Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report\u2014second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med. 2006;47(4):373\u201380.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"398_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/sim.4780040211","volume":"4","author":"O Miettinen","year":"1985","unstructured":"Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213\u201326.","journal-title":"Stat Med"},{"issue":"6","key":"398_CR20","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/bcp.13094","volume":"82","author":"JH Williams","year":"2016","unstructured":"Williams JH, Hutmacher MM, Zierhut ML, Becker JC, Gumbiner B, Spencer-Green G, et al. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab. Br J Clin Pharmacol. 2016;82(6):1568\u201379.","journal-title":"Br J Clin Pharmacol"},{"key":"398_CR21","unstructured":"EMA. MabThera. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera. Accessed Aug 22 2018."},{"key":"398_CR22","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-Hodgkin\u2019s lymphomas. Version 3.2019. Fort Washington. 2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed 30 July 2019."},{"issue":"8","key":"398_CR23","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","volume":"4","author":"WS Kim","year":"2017","unstructured":"Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017;4(8):e362\u201373.","journal-title":"Lancet Haematol."},{"issue":"8","key":"398_CR24","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","volume":"4","author":"W Jurczak","year":"2017","unstructured":"Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350\u201361.","journal-title":"Lancet Haematol."},{"issue":"11","key":"398_CR25","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","volume":"5","author":"M Ogura","year":"2018","unstructured":"Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018;5(11):e543\u201353.","journal-title":"Lancet Haematol."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00398-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-019-00398-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00398-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T20:05:05Z","timestamp":1607371505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-019-00398-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s40259-019-00398-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,9]]},"assertion":[{"value":"9 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in compliance with the ethical principles originating in, or derived from, the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines, and was reviewed and approved by institutional review boards and\/or independent ethics committees. In addition, all local regulatory requirements were followed, particularly those affording greater protection to the safety of trial participants. All subjects provided informed consent before undergoing any screening procedures. The study was sponsored by Pfizer and is registered on ClinicalTrials.gov Identifier (NCT02213263) and EudraCT (2014-000132-41).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.P. Sharman received consulting fees and research funding from Pfizer Inc, Genentech, and TG Therapeutics. A.M. Liberati declares no competing interests. K. Ishizawa received grants from Pfizer and personal fees from Chugai during the conduct of the study, grants and personal fees from Kyowa Kirin, grants from Sanofi and AbbVie, personal fees from MSD, Janssen, Celgene, Eizai, Ono, and Novartis, grants from Otsuka, and grants and personal fees from Takeda outside the submitted work. T. Khan is a full-time employee of, and declares stock holdings or stock options from, Pfizer Inc. A. Alcasid is a full-time employee of Pfizer Inc. J.A. Rosenberg and J. Robbins were employees of, and held stock holdings or stock options from, Pfizer Inc at the time of the study. I. Aurer received research funding and honoraria from Roche and Pfizer Inc, and consultancy fees from Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Upon request, and subject to certain criteria, conditions, and exceptions (see\n                      \n                      for more information), Pfizer will provide access to individual de-identified\u00a0participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the USA and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24\u00a0months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}}]}}